Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Ocugen, Inc.
  6. News
  7. Summary
    OCGN   US67577C1053


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Ocugen : Corporate Deck

01/06/2021 | 07:40am EDT

Our Mission is to

Develop Gene Therapies to Cure

Blindness Diseases


Develop a Vaccine to fight



Corporate Deck: January 2021

Forward Looking Statement

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our business strategy, future results of operations and financial position, prospective products, product approvals, research and development costs, timing and likelihood of success, estimated market size or growth, and plans and objectives of management for future operations, are forward-looking statements. When used in this presentation, the words "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Forward-looking statements involve known and unknown risks, uncertainties and other factors, including those risks set forth in the Company's filings with the Securities and Exchange Commission, which are available at www.sec.gov, that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information available to management as of the date of this presentation. Our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

This presentation includes estimates by us of statistical data relating to market size and growth and other estimated data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. This presentation also includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe these industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data.

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

©2021 Ocugen. All Rights Reserved.


Ocugen Overview

Developing transformative therapies for blindness diseases and a vaccine for COVID-19






  • Potential for one product to treat many diseases & multi-factor approach (POC study results published in Nature)
  • OCU400 (AAV-NR2E3): 4 FDA Orphan Drug Designations with the potential to treat broad Retinitis Pigmentosa (RP), which has over 150 gene mutations, in lieu of developing separate therapies for each mutation under traditional gene therapy - initiation of Phase 1/2a within a year
  • OCU410 (AAV-RORA): Potential to treat dry age-related macular degeneration (Dry AMD) through multi-factor treatment approach - initiation of Phase 1/2 in 2022
  • Strategic manufacturing partnership with CanSinoBio (~$7B market cap) - sets clear path for critical manufacturing
  • OCU200: Targeting major retinal diseases: Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and Wet Age- Related Macular Degeneration (Wet AMD) (estimated global market size over $10B) - initiation of Phase 1/2 in 2022
  • Novel MoA: Potential to initially treat non-responders to anti-VEGF/ therapies (~50% of patients)
  • COVAXIN: Whole-virion inactivated COVID-19 vaccine candidate (with adjuvant). Co-develop with Bharat Biotech for the US market (currently received EUA in India). Standard vaccine storage condition (2-8°C)
  • Promising safety and immunogenicity demonstrated by the Phase 1 and Phase 2 trials in India. Currently in Phase 3 trials in India involving about 26,000 volunteers
  • Potential coverage against multiple protein antigens of the virus and potentially applicable to broader population

©2021 Ocugen. All Rights Reserved.


Ophthalmology and Vaccine-Focused Expertise

Leadership Team

Shankar Musunuri, PhD, MBA

Mohamed Genead, MD

Sanjay Subramanian, MBA

Chairman, CEO and Co-Founder

Acting CMO and Chair of SAB

CFO and Head of Corporate Development

Vijay Tammara, PhD

Arun Upadhyay, PhD

Jessica Crespo, CPA

SVP, Regulatory & Quality

Head of Research & Development

Corporate Controller

©2021 Ocugen. All Rights Reserved.


This is an excerpt of the original content. To continue reading it, access the original document here.


Ocugen Inc. published this content on 05 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 January 2021 12:39:01 UTC

© Publicnow 2021
All news about OCUGEN, INC.
10/21INSIDER SELL : Ocugen
10/19OCUGEN INC : . to present pre-clinical data for OCU410 at 2nd Annual Dry AMD Therapeutic D..
10/16OCUGEN INC : . Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/15INSIDER SELL : Ocugen
10/15OCUGEN : Thinking about buying stock in Plug Power, Cemtrex, Ocugen, NRX Pharmaceuticals, ..
10/14SOCIAL BUZZ : Ocugen, AMC, BlackBerry Top WallstreetBets Stock Gainers at Thursday Close
10/14SOCIAL BUZZ : BlackBerry Seeing Late Day Strength
10/13SOCIAL BUZZ : Plug Power Surges, Ocugen Slides
10/12CLOSE UPDATE : US Stocks Waver Ahead of Earnings, FOMC Minutes; Investors Remain Cautious ..
10/12SOCIAL BUZZ : Wallstreetbets Top Stocks Ocugen, SoFi, Tesla Gain as Broader Market Slides
More news
Analyst Recommendations on OCUGEN, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -55,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -29,0x
Yield 2021 -
Capitalization 1 654 M 1 654 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 9,15x
Nbr of Employees 15
Free-Float 97,5%
Duration : Period :
Ocugen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OCUGEN, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 8,32 $
Average target price 8,88 $
Spread / Average Target 6,67%
EPS Revisions
Managers and Directors
Shankar Musunuri Chairman & Chief Executive Officer
Sanjay Subramanian CFO, Secretary & Head-Corporate Development
Arun Upadhyay Vice President-Research & Development
Bruce D. Forrest Chief Medical Officer
Uday B. Kompella Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OCUGEN, INC.354.64%1 654
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455